Merck's Propecia
This article was originally published in The Tan Sheet
Executive Summary
Rx hair regrowth treatment (finasteride) is "not an effective treatment for women with hair loss," the company says May 4, reporting new study results. The product was approved by FDA for Rx use in men Dec. 19 ("The Tan Sheet" Jan. 5, pp. 14-16). Presented at a conference in Brussels, the study showed that among 65 post-menopausal women treated with Propecia for one year, there was an 8.4% decrease in hair count in the scalp areas examined; among 69 women given placebo, there was a 6.5% decrease. The new results may bolster Rogaine sales. Pharmacia & Upjohn sells Rogaine for Women (minoxidil 2% solution) and is conducting a study on the use of topical 5% minoxidil solution in women, expected to be completed in 1999. Minoxidil 5% is the active ingredient in P&U's Rogaine Extra Strength For Men, launched in January ("The Tan Sheet" Jan. 5, p. 13)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning